Brief: Biofrontera Inc - Receives FDA Approval For New Formulation Of Ameluz(R)
10/10/2023 14:24
Oct 10 (Reuters) - Biofrontera Inc BFRI.O :
* BIOFRONTERA INC - RECEIVES FDA APPROVAL FOR NEW
FORMULATION OF
AMELUZ(R)
* BIOFRONTERA INC - PATENT APPLICATION FILED WITH POTENTIAL
TO
EXTEND AMELUZ PROTECTION TO 2043
* BIOFRONTERA INC - ANTICIPATE THAT NEW FORMULATION, WHICH
WILL BE
IMPLEMENTED IN ALL U.S. AMELUZ PRODUCTION BEGINNING IN 2024
Source text for Eikon: ID:
Further company coverage: BFRI.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Biofrontera
See all newsBrief: Biofrontera Submits Supplemental New Drug Application To FDA To Expand Ameluz® Red Light Pdt To Actinic Keratoses On The Full Body
Biofrontera Inc reports results for the quarter ended June 30 - Earnings Summary
Biofrontera Q2 revenue rises on higher volume, pricing
Biofrontera Inc expected to post a loss of 10 cents a share - Earnings Preview
Biofrontera Q1 revenue rises on higher Ameluz sales